Peter C Adamson
Overview
Explore the profile of Peter C Adamson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
4841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valtingojer I, Lievre S, Bordes P, Paranjpe K, Thompson W, Shah S, et al.
Handb Exp Pharmacol
. 2024 Aug;
286:33-50.
PMID: 39177748
The outcome for children with cancer has improved significantly over the past 60 years, with more than 80% of patients today becoming 5-year survivors. Despite this progress, cancer remains the...
2.
Mizuno K, Capparelli E, Fukuda T, Dong M, Adamson P, Blumer J, et al.
Clin Pharmacol Ther
. 2023 Jun;
114(2):459-469.
PMID: 37316457
Ethosuximide was identified as the optimal option for new-onset childhood absence epilepsy (CAE) in a randomized, two-phase dose escalation comparative effectiveness trial of ethosuximide, lamotrigine, and valproic acid. However, 47%...
3.
Miller T, Getz K, Li Y, Demissei B, Adamson P, Alonzo T, et al.
Lancet Haematol
. 2022 Jul;
9(9):e678-e688.
PMID: 35870472
Background: Adverse events are often misreported in clinical trials, leading to an incomplete understanding of toxicities. We aimed to test automated laboratory adverse event ascertainment and grading (via the ExtractEHR...
4.
5.
Burke G, Minard-Colin V, Auperin A, Alexander S, Pillon M, Delgado R, et al.
J Clin Oncol
. 2022 Apr;
40(18):2064-2066.
PMID: 35377710
No abstract available.
6.
Pearson A, Weiner S, Adamson P, Karres D, Reaman G, Rousseau R, et al.
Eur J Cancer
. 2022 Mar;
166:145-164.
PMID: 35290915
Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving survival and reducing long-term side-effects for children and adolescents with cancer. The international multi-stakeholder organisation ACCELERATE was...
7.
Burke G, Minard-Colin V, Auperin A, Alexander S, Pillon M, Delgado R, et al.
J Clin Oncol
. 2021 Sep;
39(33):3716-3724.
PMID: 34570655
Purpose: A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma...
8.
Su J, Kilburn L, Mansur D, Krailo M, Buxton A, Adekunle A, et al.
Neuro Oncol
. 2021 Aug;
24(4):655-664.
PMID: 34347089
Background: A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children's...
9.
Adamson P, Perilongo G
Pediatr Blood Cancer
. 2021 Apr;
68 Suppl 2:e29009.
PMID: 33818889
No abstract available.
10.
Foster J, Voss S, Hall D, Minard C, Balis F, Wilner K, et al.
Clin Cancer Res
. 2021 Feb;
27(13):3543-3548.
PMID: 33568345
Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments...